|
Active substance |
trastuzumab emtansine |
|
Holder |
NV Roche SA |
|
Status |
Closed |
|
Indication |
as a single agent for the adjuvant treatment of adult patients with HER2 positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy. |
|
Public documents |
|
|
Laatste update |
25/02/2021 |
Kadcyla
Last updated on 13/09/2024